Catalog No. | VK421046 |
---|---|
Description | Felvizumab [HuRSV19VHFNS/VK, RSHZ19, RSV monoclonal antibody, SB209763] is a humanised monoclonal antibody (IgG1) prepared by the humanization of an F protein-specific murine MAb. In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999). |
Species reactivity | HRSV-A |
Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
Host species | Humanized |
Isotype | IgG1, kappa |
Expression system | Mammalian Cells |
Clonality | Monoclonal |
Target | F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1 |
Endotoxin level | Please contact the lab for this information. |
Purity | >95% purity as determined by SDS-PAGE. |
Purification | Protein A/G purified from cell culture supernatant. |
Accession | P03420 |
Form | Liquid |
Storage buffer | 0.01M PBS, pH 7.4. |
Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names | SB209763, HuRSV19VHFNS/VK, RSHZ19monoclonalantibody, SB209763, CAS:167747-20-8 |
Background | Felvizumab is a humanized monoclonal antibody against respiratory syncytial virus. |
Note | For research use only. Not suitable for clinical or therapeutic use. |
SDS-PAGE for Research Grade Felvizumab.
+33(0)3 90 20 54 70
19 rue de la Haye 67300 Schiltigheim France